ZENTALIS PHARMACEUTICALS INC
ZNTLNASDAQ🏆 #3572 by market capEarnings Nov 9US Equity
$1.97▼ $0.09 (−4.14%)
Market closed · at closeTrack ZNTL
Get earnings, price moves & breaking news on Telegram
24h▼ 4.1%
7d▼ 10.5%
14d▼ 8.4%
30d▼ 28.8%
ytd▲ 46.5%
1y▲ 32.7%
🏦Market Cap
$186M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $1.97 – $2.10
- 52-Week Range
- $1.21 – $6.95
- Volume (shares)
- 165,768
- Avg Volume (shares)
- —
- Shares Outstanding
- 94.7M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.91
- Dividend Yield
- —
- Dilution (1yr)
- +0.6%
ZENTALIS PHARMACEUTICALS INC
ZNTLFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$153M▼ −20.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$125M▼ −26.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
71.7M▲ +0.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$4M▲ +$5M YoY
StockOtter · stockotter.spaceAbout ZENTALIS PHARMACEUTICALS INC
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
17 analysts
Strong Buy5
Buy6
Hold6
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.